220 related articles for article (PubMed ID: 26979081)
21. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells.
Florio T; Barbieri F
Drug Discov Today; 2012 Oct; 17(19-20):1103-10. PubMed ID: 22704957
[TBL] [Abstract][Full Text] [Related]
22. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
23. Delivery systems and molecular targets of mechanism-based therapies for GBM.
Phuphanich S; Brat DJ; Olson JJ
Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
[TBL] [Abstract][Full Text] [Related]
24. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
25. Korean Red ginseng extract inhibits glioblastoma propagation by blocking the Wnt signaling pathway.
Ham SW; Kim JK; Jeon HY; Kim EJ; Jin X; Eun K; Park CG; Lee SY; Seo S; Kim JY; Choi SH; Hong N; Lee YY; Kim H
J Ethnopharmacol; 2019 May; 236():393-400. PubMed ID: 30878548
[TBL] [Abstract][Full Text] [Related]
26. Novel delivery strategies for glioblastoma.
Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
[TBL] [Abstract][Full Text] [Related]
27. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
28. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
Jagannathan J; Prevedello DM; Dumont AS; Laws ER
Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
[TBL] [Abstract][Full Text] [Related]
29. Microglia-glioblastoma interactions: New role for Wnt signaling.
Matias D; Predes D; Niemeyer Filho P; Lopes MC; Abreu JG; Lima FRS; Moura Neto V
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):333-340. PubMed ID: 28554667
[TBL] [Abstract][Full Text] [Related]
30. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
31. Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma.
Morás AM; Henn JG; Steffens Reinhardt L; Lenz G; Moura DJ
Life Sci; 2021 Dec; 287():120128. PubMed ID: 34774874
[TBL] [Abstract][Full Text] [Related]
32. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
[TBL] [Abstract][Full Text] [Related]
33. Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells.
Warrier S; Balu SK; Kumar AP; Millward M; Dharmarajan A
Oncol Res; 2013; 21(2):93-102. PubMed ID: 24406045
[TBL] [Abstract][Full Text] [Related]
34. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.
Triscott J; Rose Pambid M; Dunn SE
Stem Cells; 2015 Apr; 33(4):1042-6. PubMed ID: 25588723
[TBL] [Abstract][Full Text] [Related]
35. The Wnt signaling pathway in cancer.
Duchartre Y; Kim YM; Kahn M
Crit Rev Oncol Hematol; 2016 Mar; 99():141-9. PubMed ID: 26775730
[TBL] [Abstract][Full Text] [Related]
36. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
[TBL] [Abstract][Full Text] [Related]
38. TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.
Litak J; Grochowski C; Litak J; Osuchowska I; Gosik K; Radzikowska E; Kamieniak P; Rolinski J
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354122
[TBL] [Abstract][Full Text] [Related]
39. Use of nanoparticles for drug delivery in glioblastoma multiforme.
Jain KK
Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
[TBL] [Abstract][Full Text] [Related]
40. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
